# Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers

> **NCT02777710** · PHASE1 · COMPLETED · sponsor: **Centre Leon Berard** · enrollment: 48 (actual)

## Conditions studied

- Colorectal Cancer
- Pancreatic Cancer
- Metastatic Cancer
- Advanced Cancer

## Interventions

- **DRUG:** Pexidartinib
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT02777710
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2019-11
- **Final completion:** 2019-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2021-09-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02777710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02777710, "Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02777710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*